New ointment could tame HHT nosebleeds
NCT ID NCT07667413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new nasal ointment called TOR-582, which contains sirolimus, in 27 adults with hereditary hemorrhagic telangiectasia (HHT) who have frequent nosebleeds. Participants apply the ointment inside their nostrils twice daily for 12 weeks, with different strengths tested to find the safest dose. The goal is to see if the treatment is safe enough to study further, potentially offering a less invasive way to manage nosebleeds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sirolimus ointment (TOR-582)
- What this could lead to
- If this works, it could lead to a new, non-invasive treatment to reduce nosebleeds in people with HHT, improving daily life and reducing the need for medical procedures.
- What could go wrong
- This is a very early phase 1 trial with only 27 participants, focused on safety and dosing. It may not show clear benefit, and side effects or lack of effectiveness could prevent further development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPISTAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
- New drug aims to stop nosebleeds in rare blood vessel disorder
- Nosebleed breakthrough? gel vs. jelly in new study
- Can a plant gel beat vaseline for nosebleeds?
- New drug aims to stop nosebleeds in rare genetic disorder